急性卒中诊疗质量与长期生活质量及生存的关系:澳大利亚卒中临床登记研究
该研究基于澳大利亚卒中临床登记2010至2014年42家医院17 585例卒中入院数据,采用多变量回归分析急性卒中单元(ASU)诊疗、出院降压药处方和出院护理计划与180天生存及健康相关生活质量(HRQoL)的关联。结果显示接受最佳实践推荐医院诊疗的患者长期生存和HRQoL更优,且获益随所接受诊疗流程数量累积。
要点
- 接受急性卒中单元诊疗与180天内死亡风险降低和HRQoL改善相关。
- 出院时接受ASU+降压药治疗者180天生存优于仅ASU诊疗者。
- 脑出血患者接受含出院流程的集束化诊疗HRQoL提升幅度最大。
核心结论
- 接受最佳实践推荐医院诊疗的卒中患者长期生存和HRQoL更好。
研究设计与样本
- 数据来自澳大利亚卒中临床登记2010至2014年42家医院(77%位于都市)的17 585例卒中入院,中位年龄77岁,47%女性,81%在ASU管理,80%为缺血性卒中。
- 采用多变量回归分析3项干预(ASU诊疗、出院降压药处方、出院护理计划)及其组合与180天生存和HRQoL(EuroQoL 5维问卷视觉模拟量表)的关联,并按卒中类型分层。
- 同时评估患者接受诊疗流程数量与结局的关系。
主要发现
- 结局获益随患者接受的诊疗流程数量累积。
- ASU诊疗与180天内死亡可能性降低相关(风险比0.49;95%CI 0.43-0.56)且HRQoL更好(系数21.34;95%CI 15.50-27.18)。
- 出院患者中,ASU+降压药治疗相比仅ASU诊疗提供更高的180天生存(风险比0.45;95%CI 0.38-0.52 vs 风险比0.64;95%CI 0.54-0.76)。
- 接受含出院流程集束化诊疗的脑出血患者HRQoL提升最大(增幅范围11%-19%)。
临床怎么用
- 应推动卒中患者接受急性卒中单元诊疗、出院降压药处方和出院护理计划等最佳实践推荐干预。
- 关注诊疗流程数量的累积效应,尽可能完整地落实推荐流程以改善长期生存和HRQoL。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Uncertainty exists over whether quality improvement strategies translate into better health-related quality of life (HRQoL) and survival after acute stroke. We aimed to determine the association of best practice recommended interventions and outcomes after stroke. METHODS: Data are from the Australian Stroke Clinical Registry during 2010 to 2014. Multivariable regression was used to determine associations between 3 interventions: received acute stroke unit (ASU) care and in various combinations with prescribed antihypertensive medication at discharge, provision of a discharge care plan, and outcomes of survival and HRQoL (EuroQoL 5-dimensional questionnaire visual analogue scale) at 180 days, by stroke type. An assessment was also made of outcomes related to the number of processes patients received. RESULTS: There were 17 585 stroke admissions (median age 77 years, 47% female; 81% managed in ASUs; 80% ischemic stroke) from 42 hospitals (77% metropolitan) assessed. Cumulative benefits on outcomes related to the number of care processes received by patients. ASU care was associated with a reduced likelihood of death (hazard ratio, 0.49; 95% confidence interval, 0.43-0.56) and better HRQoL (coefficient, 21.34; 95% confidence interval, 15.50-27.18) within 180 days. For those discharged from hospital, receiving ASU+antihypertensive medication provided greater 180-day survival (hazard ratio, 0.45; 95% confidence interval, 0.38-0.52) compared with ASU care alone (hazard ratio, 0.64; 95% confidence interval, 0.54-0.76). HRQoL gains were greatest for patients with intracerebral hemorrhage who received care bundles involving discharge processes (range of increase, 11%-19%). CONCLUSIONS: Patients with stroke who receive best practice recommended hospital care have improved long-term survival and HRQoL.
引用
- Cadilhac DA, Andrew NE, Lannin NA, et al. Quality of Acute Care and Long-Term Quality of Life and Survival: The Australian Stroke Clinical Registry. Stroke. 2017. PMID: 28258253. doi:10.1161/STROKEAHA.116.015714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。